The intestinal protozoa: Emerging impact on global health and development

Current Opinion in Gastroenterology

Volumn 31, Issue 1, 2015, Pages 38-44

  Turkeltaub, Joshua A ^a   McCarty Iii, Thomas R ^b   Hotez, Peter J ^c,d  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b YALE NEW HAVEN HOSPITAL   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

Amebiasis; Blastocystis; Cryptosporidiosis; Dientamoeba; Intestinal protozoa

Indexed keywords

AMEBIASIS; BLASTOCYSTIS; BLASTOCYSTIS HOMINIS; CRYPTOSPORIDIOSIS; DEVELOPING COUNTRY; DIENTAMOEBA; GASTROINTESTINAL INFECTION; HELMINTHIASIS; HUMAN; INCOME; INTESTINAL PROTOZOA; MULTICENTER STUDY (TOPIC); NONHUMAN; PREVALENCE; PROTOZOAL INFECTION; PROTOZOON; PUBLIC HEALTH; REVIEW; TROPICAL DISEASE; BLASTOCYSTIS INFECTIONS; COMMUNICABLE DISEASES, EMERGING; DIENTAMOEBIASIS; DYSENTERY, AMEBIC; HEALTH; INTESTINAL DISEASES, PARASITIC; PROTOZOAN INFECTIONS; STATISTICS AND NUMERICAL DATA;

BLASTOCYSTIS INFECTIONS; COMMUNICABLE DISEASES, EMERGING; CRYPTOSPORIDIOSIS; DEVELOPING COUNTRIES; DIENTAMOEBIASIS; DYSENTERY, AMEBIC; GLOBAL HEALTH; HUMANS; INTESTINAL DISEASES, PARASITIC; PROTOZOAN INFECTIONS;

EID: 84917728221     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0000000000000135     Document Type: Review

References (70)

1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380:2095-2128.
2. Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380:2197-2223.
3. Hotez PJ. Could nitazoxanide be added to other essential medicines for integrated neglected tropical disease control and elimination? PLoS Negl Trop Dis 2014; 8:e2758.
4. Kotloff KL, Nataro JP, Blackwelder WC, et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet 2013; 382:209-222.
5. Muhsen K, Levine MM. A systematic review and meta-analysis of the association between Giardia lamblia and endemic pediatric diarrhea in developing countries. Clin Infect Dis 2012; 55 (Suppl 4):S271-S293.
6. Guerrant RL. Cryptosporidiosis: an emerging, highly infectious threat. Emerg Infect Dis 1997; 3:51-57.
7. Cama VA, Bern C, Roberts J, et al. Cryptosporidium species and subtypes and clinical manifestations in children, Peru. Emerg Infect Dis 2008; 14:1567-1574
8. Adamu H, Petros B, Zhang G, et al. Distribution and clinical manifestations of Cryptosporidium species and subtypes in HIV/AIDS patients in Ethiopia. PLoS Negl Trop Dis 2014; 8:e2831.
9. Shirley DA, Moonah SN, Kotloff KL. Burden of disease from cryptosporidiosis. Curr Opin Infect Dis 2012; 25:555-563.
10. Xiao L. Molecular epidemiology of cryptosporidiosis: an update. Exp Parasitol 2010; 124:80-89.
11. Global Atlas of Helminth Infections [Internet]. London: Global Atlas of Helminth Infections. London School of Hygiene & Tropical Medicine; 2010. http://www.thiswormyworld.org/[Accessed 13 June 2014].
12. Kaushik K, Khurana S, Wanchu A, Malla N. Evaluation of staining techniques, antigen detection and nested PCR for the diagnosis of cryptosporidiosis in HIV seropositive and seronegative patients. Acta tropica 2008; 107:1-7.
13. Current WL, Garcia LS. Cryptosporidiosis. Clin Microbiol Rev 1991; 4:325-358.
14. Chalmers RM, Campbell BM, Crouch N, et al. Comparison of diagnostic sensitivity and specificity of seven Cryptosporidium assays used in the UK. J Med Microbiol 2011; 60 (Pt 11):1598-1604.
15. Mejia R, Vicuna Y, Broncano N, et al. A novel, multiparallel, real-time polymerase chain reaction approach for eight gastrointestinal parasites provides improved diagnostic capabilities to resource-limited at-risk populations. Am J Trop Med Hyg 2013; 88:1041-1047.
16. Buckner FS, Waters NC, Avery VM. Recent highlights in antiprotozoan drug development and resistance research. Int J Parasitol Drugs Drug Resist 2012; 2:230-235.
17. Artz JD, Wernimont AK, Allali-Hassani A, et al. The Cryptosporidium parvum kinome. BMC Genomics 2011; 12:478.
18. Fritzler JM, Zhu G. Novel anti-Cryptosporidium activity of known drugs identified by high-throughput screening against parasite fatty acyl-CoA binding protein (ACBP). J Antimicrob Chemother 2012; 67:609-617.
19. Harris JR, Greene SK, Thomas TK, et al. Effect of a point-of-use water treatment and safe water storage intervention on diarrhea in infants of HIVinfected mothers. J Infect Dis 2009; 200:1186-1193.
20. Barzilay EJ, Aghoghovbia TS, Blanton EM, et al. Diarrhea prevention in people living with HIV: an evaluation of a point-of-use water quality intervention in Lagos, Nigeria. AIDS Care 2011; 23:330-339.
21. Lule JR, Mermin J, Ekwaru JP, et al. Effect of home-based water chlorination and safe storage on diarrhea among persons with human immunodeficiency virus in Uganda. Am J Trop Med Hyg 2005; 73:926-933.
22. Centers for Disease Control. Global Water, Sanitation, and Hygiene (WASH) program impact. http://www.cdc.gov/healthywater/pdf/global/programs/GlobalWASH-Program-Impact-Sept2012.pdf. [Accessed 12 May 2014].
23. de Graaf DC, Spano F, Petry F, et al. Speculation on whether a vaccine against cryptosporidiosis is a reality or fantasy. Int J Parasitol 1999; 29:1289-1306.
24. Manque PA, Tenjo F, Woehlbier U, et al. Identification and immunological characterization of three potential vaccinogens against Cryptosporidium species. Clin Vaccine Immunol 2011; 18:1796-1802.
25. Meade BD, Plotkin SA, Locht C. Possible options for new pertussis vaccines. J Infect Dis 2014; 209 (Suppl 1):S24-S27
26. Ximenez C, Cerritos R, Rojas L, et al. Human amebiasis: breaking the paradigm? Int J Environ Res Public Health 2010; 7:1105-1120.
27. Heredia RD, Fonseca JA, Lopez MC. Entamoeba moshkovskii perspectives of a new agent to be considered in the diagnosis of amebiasis. Acta Tropica 2012; 123:139-145.
28. Ximenez C, Moran P, Rojas L, et al. Reassessment of the epidemiology of amebiasis: state of the art. Infect Genet Evol 2009; 9:1023-1032.
29. Stauffer W, Abd-Alla M, Ravdin JI. Prevalence and incidence of Entamoeba histolytica infection in South Africa and Egypt. Arch Med Res 2006; 37:266-269.
30. Petri W, Singh U. Enteric amebiasis. In: Guerrant R, Walker DH, Weller PF, editors. Tropical infectious diseases: principles, pathogens, and practice. 2nd ed. Philadelphia: Elsevier; 2006. p. 967.
31. Bansal D, Malla N, Mahajan RC. Drug resistance in amoebiasis. Indian J Med Res 2006; 123:115-118.
32. Zeyrek FY, Turgay N, Unver A, et al. Differentiation of Entamoeba histolytica/Entamoeba dispar by the polymerase chain reaction in stool samples of patients with gastrointestinal symptoms in the Sanliurfa Province. Turkiye Parazitol Derg 2013; 37:174-178.
33. Zermeno V, Ximenez C, Moran P, et al. Worldwide genealogy of Entamoeba histolytica: an overview to understand haplotype distribution and infection outcome. Infect Genet Evol 2013; 17:243-252.
34. Leitsch D, Kolarich D, Wilson IB, et al. Nitroimidazole action in Entamoeba histolytica: a central role for thioredoxin reductase. PLoS Biol 2007; 5:e211.
35. Li E, Stanley SL Jr. Protozoa. Amebiasis. Gastroenterol Clin North Am 1996; 25:471-492.
36. Rossignol JF, Kabil SM, El-Gohary Y, Younis AM. Nitazoxanide in the treatment of amoebiasis. Trans R Soc Trop Med Hyg 2007; 101:1025-1031.
37. Debnath A, Shahinas D, Bryant C, et al. Hsp90 inhibitors as new leads to target parasitic diarrheal diseases. Antimicrob Agents Chemother 2014; 58:4138-4144.
38. Haque R, Duggal P, Ali IM, et al. Innate and acquired resistance to amebiasis in Bangladeshi children. J Infect Dis 2002; 186:547-552.
39. Haque R, Mondal D, Duggal P, et al. Entamoeba histolytica infection in children and protection from subsequent amebiasis. Infect Immun 2006; 74:904-909.
40. Stanley SL Jr. Protective immunity to amebiasis: new insights and new challenges. J Infect Dis 2001; 184:504-506.
41. Lotter H, Tannich E. The current status of an amebiasis vaccine. Arch Med Res 2006; 37:292-296.
42. Stanley SL Jr. Progress towards development of a vaccine for amebiasis. Clin Microbiol Rev 1997; 10:637-649.
43. Huston CD, Petri WA Jr. Host-pathogen interaction in amebiasis and progress in vaccine development. Eur J Clin Microbiol 1998; 17:601-614.
44. Quach J, St-Pierre J, Chadee K. The future for vaccine development against Entamoeba histolytica. Hum Vaccin Immunother 2014; 10:1514-1521.
45. Stensvold CR. Blastocystis: Genetic diversity and molecular methods for diagnosis and epidemiology. Trop Parasitol 2013; 3:26-34.
46. WHO. Guidelines for drinking-water quality. 3rd ed. Incorporating first and second addenda. Geneva: WHO; 2008. pp. 262-262b. http://www.who.int/water-sanitation-health/dwq/GDWPRecomdrev1and2.pdf. [Accessed 12 June 2014].
47. Tan KS. New insights on classification, identification, and clinical relevance of Blastocystis spp. Clin Microbiol Rev 2008; 21:639-665.
48. Dogruman-Al F, Simsek Z, Boorom K, et al. Comparison of methods for detection of Blastocystis infection in routinely submitted stool samples, and also in IBS/IBD Patients in Ankara, Turkey. PloS One 2010; 5:e15484.
49. Wang W, Owen H, Traub RJ, et al. Molecular epidemiology of Blastocystis in pigs and their in-contact humans in Southeast Queensland, Australia, and Cambodia. Vet Parasitol 2014; 203 (3-4):264-269.
50. Basak S, Rajurkar MN, Mallick SK. Detection of Blastocystis hominis: a controversial human pathogen. Parasitol Res 2014; 113:261-265.
51. Mumcuoglu I, Coskun FA, Aksu N, et al. [Role of Dientamoeba fragilis and Blastocystis spp. in Irritable Bowel Syndrome]. Turkiye Parazitol Derg 2013; 37:73-77.
52. Yakoob J, Jafri W, Beg MA, et al. Blastocystis hominis and Dientamoeba fragilis in patients fulfilling irritable bowel syndrome criteria. Parasitol Res 2010; 107:679-684.
53. Roberts T, Barratt J, Harkness J, et al. Comparison of microscopy, culture, and conventional polymerase chain reaction for detection of Blastocystis sp. in clinical stool samples. American J Trop Med Hyg 2011; 84:308-312.
54. Stensvold CR, Arendrup MC, Jespersgaard C, et al. Detecting Blastocystis using parasitologic and DNA-based methods: a comparative study. Diagn Microbiol Infect Dis 2007; 59:303-307.
55. Parkar U, Traub RJ, Kumar S, et al. Direct characterization of Blastocystis from faeces by PCR and evidence of zoonotic potential. Parasitology 2007; 134 (Pt 3):359-367.
56. Poirier P, Wawrzyniak I, Albert A, et al. Development and evaluation of a realtime PCR assay for detection and quantification of Blastocystis parasites in human stool samples: prospective study of patients with hematological malignancies. J Clin Microbiol 2011; 49:975-983.
57. Mahdi NK SSTeom, praziquantel and cotrimoxazole on Blastocystis hominis. Int J Glob Educ 2005. 1(5).
58. Boorom KF, Smith H, Nimri L, et al. Oh my aching gut: irritable bowel syndrome, Blastocystis, and asymptomatic infection. Parasit Vectors 2008; 1:40.
59. Rossignol JF, Kabil SM, Said M, et al. Effect of nitazoxanide in persistent diarrhea and enteritis associated with Blastocystis hominis. Clin Gastroenterol Hepatol 2005; 3:987-991.
60. van Hellemond JJ, Molhoek N, Koelewijn R, et al. Is paromomycin the drug of choice for eradication of Blastocystis in adults? J Infect Chemother 2013; 19:545-548.
61. Dinleyici EC, Eren M, Dogan N, et al. Clinical efficacy of Saccharomyces boulardii or metronidazole in symptomatic children with Blastocystis hominis infection. Parasitol Res 2011; 108:541-545.
62. Maritz JM, Land KM, Carlton JM, Hirt RP. What is the importance of zoonotic trichomonads for human health? Trends Parasitol 2014; 30:333-341.
63. Clark CG, Roser D, Stensvold CR. Transmission of Dientamoeba fragilis: pinworm or cysts? Trends Parasitol 2014; 30:136-140.
64. Barratt JL, Harkness J, Marriott D, et al. The ambiguous life of Dientamoeba fragilis: the need to investigate current hypotheses on transmission. Parasitology 2011; 138:557-572.
65. Stark D, Barratt J, Roberts T, et al. A review of the clinical presentation of dientamoebiasis. Am J Trop Med Hyg 2010; 82:614-619.
66. Nagata N, Marriott D, Harkness J, et al. Current treatment options for infections. Int J Parasitol Drugs Drug Resist 2012; 2:204-215.
67. Lagace-Wiens PR, VanCaeseele PG, Koschik C. Dientamoeba fragilis: an emerging role in intestinal disease. CMAJ 2006; 175:468-469.
68. Stark D, Beebe N, Marriott D, et al. Prospective study of the prevalence, genotyping, and clinical relevance of Dientamoeba fragilis infections in an Australian population. J Clin Microbiol 2005; 43:2718-2723.
69. Nagata N, Marriott D, Harkness J, et al. Current treatment options for Dientamoeba fragilis infections. Int J Parasitol Drugs Drug Resist 2012; 2:204-215.
70. Roser D, Simonsen J, Stensvold CR, et al. Metronidazole therapy for treating dientamoebiasis in children is not associated with better clinical outcomes: a randomized, double-blinded and placebo-controlled clinical trial. Clin Infect Dis 2014; 58:1692-1698.